Orgenesis Completes Sale of Masthercell Subsidiary; Receives Approximately $127 Million in Net Proceeds
11 févr. 2020 08h00 HE
|
Orgenesis Inc.
Sale reflects culmination of successful CDMO strategy initiated in 2015 and 59% 5-year CAGR of Masthercell under Orgenesis’ leadership Reports rapid progress in roll-out of point-of-care (POCare)...
Orgenesis Announces Agreement for the Sale of Masthercell Global, its Contract Development and Manufacturing Organization (CDMO) Subsidiary
03 févr. 2020 07h35 HE
|
Orgenesis Inc.
GERMANTOWN, Md., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), today announced that Catalent Pharma Solutions has agreed to acquire Masthercell...
Orgenesis Inc. Announces $9.2 Million Private Placement
21 janv. 2020 07h00 HE
|
Orgenesis Inc.
GERMANTOWN, Md., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO...
Orgenesis Appoints Industry Veteran Mario Philips to its Board of Directors
13 janv. 2020 09h25 HE
|
Orgenesis Inc.
GERMANTOWN, Md., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO...
Orgenesis Announces Addition of University of California, Davis, to its Point of Care Network; UC Davis Health to Utilize Orgenesis’ Point of Care Platform for the Development, Commercialization and Supply of Cell and Gene Therapy Products
10 janv. 2020 07h00 HE
|
Orgenesis Inc.
GERMANTOWN, Md., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS), a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development services,...
Orgenesis Announces Receipt of the $6.6 Million Second Milestone Payment into Masthercell Global Subsidiary
23 déc. 2019 12h24 HE
|
Orgenesis Inc.
GERMANTOWN, Md., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS), a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development services,...
Orgenesis and Theracell to Launch Point of Care Cell and Gene Therapy Centers within HYGEIA Group’s Hospital Network in Greece
06 déc. 2019 08h53 HE
|
Orgenesis Inc.
GERMANTOWN, Md., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO...
Orgenesis Ranked 5th Fastest Growing Technology Company in Maryland and 208th in North America on Deloitte's 2019 Technology Fast 500™
26 nov. 2019 07h00 HE
|
Orgenesis Inc.
GERMANTOWN, Md., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO...
Orgenesis Inc. Reminds Stockholders to Vote in Favor of All Proposals at the Annual Meeting of Stockholders to be Held on November 26, 2019
22 nov. 2019 12h20 HE
|
Orgenesis Inc.
GERMANTOWN, Md., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO...
Orgenesis CEO Appears as a Guest on i24 News Network
13 nov. 2019 07h00 HE
|
Orgenesis Inc.
GERMANTOWN, Md., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO...